BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

OBJECTIVES: Little is known regarding the outcomes of systemic treatments in BAP1-altered malignant pleural mesothelioma (MPM). MATERIALS AND METHODS: Forty five patients with MPM [group A: eight MPM patients with BAP1 inactivating mutation/copy number loss (FoundationOne(®) CDx/TEMPUSxT), selected...

Descripción completa

Detalles Bibliográficos
Autores principales: Dudnik, Elizabeth, Bar, Jair, Moore, Assaf, Gottfried, Teodor, Moskovitz, Mor, Dudnik, Julia, Shochat, Tzippy, Allen, Aaron M., Zer, Alona, Rotem, Ofer, Peled, Nir, Urban, Damien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987904/
https://www.ncbi.nlm.nih.gov/pubmed/33777745
http://dx.doi.org/10.3389/fonc.2021.603223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987904/
https://www.ncbi.nlm.nih.gov/pubmed/33777745
http://dx.doi.org/10.3389/fonc.2021.603223

Ejemplares similares